Rare and inherited diseases affect millions of patients worldwide, many of whom wait years for a diagnosis. Germline genomic testing, from targeted panels to exomes and genomes, has become central to shortening that diagnostic journey, provided labs can efficiently prioritize the variants that explain each patient's phenotype.
In this section, you will find our articles on rare and inherited disease genomics: germline variant interpretation, phenotype-driven prioritization, CNV detection, case studies from diagnostic labs, and updates on how SeqOne helps teams reach more diagnoses, faster.

GermVar PGx, the first module of SeqOne Preventive Genomics, supports laboratories with pharmacogenomic analysis inside the germline workflow, from star-allele calling to the guideline recommendations their experts review and report.

Valencia’s General University Hospital brought HRD testing in-house with Agilent and SeqOne. A 30-case study showed matching classifications vs. commercial assays, fewer inconclusive results, and turnaround cut from ~20 to 6-7 days.

SomaHRD v2 reaches 97.1% concordance with Myriad MyChoice CDx and a PFS hazard ratio of 0.23, with a 4.8% non-conclusive rate and results in 41 minutes.

Rewatch our webinar with Uppsala University Hospital: how one lab unified short-read, long-read, and array workflows on a single platform, and how transparent AI ranks variants so the geneticist stays in control.